Pharming Group N.V. (PHAR)
NASDAQ: PHAR · Real-Time Price · USD
14.60
-0.54 (-3.57%)
Mar 13, 2026, 3:39 PM EDT - Market open
Pharming Group Revenue
In the year 2025, Pharming Group had annual revenue of $376.13M with 26.56% growth. Pharming Group had revenue of $106.50M in the quarter ending December 31, 2025, with 14.89% growth.
Revenue (ttm)
$376.12M
Revenue Growth
+26.54%
P/S Ratio
2.69
Revenue / Employee
$931,025
Employees
404
Market Cap
1.00B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 376.13M | 78.93M | 26.56% |
| Dec 31, 2024 | 297.20M | 51.88M | 21.15% |
| Dec 31, 2023 | 245.32M | 39.69M | 19.30% |
| Dec 31, 2022 | 205.62M | 6.75M | 3.39% |
| Dec 31, 2021 | 198.87M | -13.30M | -6.27% |
| Dec 31, 2020 | 212.17M | 22.53M | 11.88% |
| Dec 31, 2019 | 189.64M | 34.36M | 22.12% |
| Dec 31, 2018 | 155.29M | 47.75M | 44.40% |
| Dec 31, 2017 | 107.54M | 90.83M | 543.88% |
| Dec 31, 2016 | 16.70M | 4.94M | 42.05% |
| Dec 31, 2015 | 11.76M | -13.88M | -54.13% |
| Dec 31, 2014 | 25.63M | 16.22M | 172.36% |
| Dec 31, 2013 | 9.41M | -4.59M | -32.77% |
| Dec 31, 2012 | 14.00M | 10.12M | 260.60% |
| Dec 31, 2011 | 3.88M | 2.41M | 163.98% |
| Dec 31, 2010 | 1.47M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Xeris Biopharma Holdings | 291.85M |
| Geron | 183.88M |
| AbCellera Biologics | 75.13M |
| EyePoint | 31.37M |
| uniQure | 16.10M |
| Aktis Oncology | 5.56M |
| Inhibrx Biosciences | 1.40M |
| Compass Therapeutics | 850.00K |
PHAR News
- 1 day ago - Pharming Group (PHGUF) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... - GuruFocus
- 1 day ago - Q4 2025 Pharming Group NV Earnings Call Transcript - GuruFocus
- 1 day ago - Earnings Scheduled For March 12, 2026 - Benzinga
- 1 day ago - Pharming Group reports fourth quarter and full year 2025 financial results, delivering strong revenue growth and profitability with positive cash flow - GlobeNewsWire
- 2 days ago - Pharming Group (XAMS:PHARM) Q4 2025 Earnings Report Preview: What to Expect - GuruFocus
- 10 days ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pharming Group N.V. - PHAR - GlobeNewsWire
- 14 days ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pharming Group N.V. - PHAR - PRNewsWire
- 15 days ago - Pharming Group to report fourth quarter and full year 2025 financial results and provide business update on March 12 - GlobeNewsWire